secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOXYTRAN, INC (BIXT)
CIK:        0001445815
Form:       8-K
Filed at:   2022-08-17T23:59:59+00:00
Accession:  0001493152-22-023258
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioxytran raises $600K in private placement for Covid-19, lung fibrosis clinical trials
--------------------------------------------------------------------------------

- Issued 1.4M shares at $0.4286/share to an accredited investor for gross proceeds of $600,000.
- Net proceeds of $576,000 after 4% placement agent fee paid to WallachBeth Capital.
- Proceeds intended for down-payment on human trials of ProLectin-M (oral) for Covid-19 and ProLectin-I (IV) for lung fibrosis.
- Shares offered on best-efforts basis; no minimum offering amount; funds available immediately upon acceptance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445815/000149315222023258/0001493152-22-023258-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445815/000149315222023258/form-8k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-023258

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer